Asset
RILUZOLE
Revenue
No revenue reported in loaded filings.
Clinical trials (1)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03520517 | phase1 | completed | 2018-02-02 | 2018-10-08 | Biohaven Pharmaceuticals, Inc. | Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS |
FDA applications (0)
This company has no applications containing this asset.